Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Role of transurethral resection of the prostate in population-based prostate cancer incidence rates.

Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA.

Am J Epidemiol. 1999 Oct 15;150(8):848-60.

PMID:
10522656
2.
3.

The diminishing role of transurethral resection of the prostate.

Merrill RM, Hunter BD.

Ann Surg Oncol. 2010 May;17(5):1422-8. doi: 10.1245/s10434-009-0896-4. Epub 2010 Jan 21.

PMID:
20091426
4.

Rising incidence of prostate cancer in Scotland: increased risk or increased detection?

Brewster DH, Fraser LA, Harris V, Black RJ.

BJU Int. 2000 Mar;85(4):463-72; discussion 472-3.

5.

Trends in prostate cancer mortality among black men and white men in the United States.

Chu KC, Tarone RE, Freeman HP.

Cancer. 2003 Mar 15;97(6):1507-16.

7.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
8.

Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.

Welch HG, Fisher ES, Gottlieb DJ, Barry MJ.

J Natl Cancer Inst. 2007 Sep 19;99(18):1395-400. Epub 2007 Sep 11.

PMID:
17848671
9.

Rise and fall of radical prostatectomy rates from 1989 to 1996.

Sheikh K, Bullock C.

Urology. 2002 Mar;59(3):378-82.

PMID:
11880074
10.
11.

Role of transurethral biopsy sampling of the prostate to diagnose prostate cancer in men undergoing surgical intervention for benign prostatic hyperplasia.

Bales GT, Flynn TJ, Kynaston HG, Golash A, Hart A, Kim HL, Gerber GS.

Tech Urol. 2000 Sep;6(3):201-4.

PMID:
10963487
12.

Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease.

Bright EA, Manuel C, Goddard JC, Khan MA.

Urol Int. 2009;83(2):171-4. doi: 10.1159/000230019. Epub 2009 Sep 10.

PMID:
19752612
13.

Recent trends in prostate cancer incidence and mortality in southeast England.

Evans HS, Møller H.

Eur Urol. 2003 Apr;43(4):337-41.

PMID:
12667713
14.

The lifetime risk of developing prostate cancer in white and black men.

Merrill RM, Weed DL, Feuer EJ.

Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):763-8.

15.

Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT).

Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE.

Urology. 1994 Nov;44(5):692-8; discussion 698-9. Review.

PMID:
7526526
16.

Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.

Jones JS, Follis HW, Johnson JR.

Prostate Cancer Prostatic Dis. 2009;12(1):57-60. doi: 10.1038/pcan.2008.14. Epub 2008 Apr 1.

PMID:
18379587
17.
18.

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.

Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS.

Cancer Causes Control. 1998 Oct;9(5):519-27.

PMID:
9934717
20.

Asymptomatic incidence and duration of prostate cancer.

Etzioni R, Cha R, Feuer EJ, Davidov O.

Am J Epidemiol. 1998 Oct 15;148(8):775-85.

PMID:
9786232

Supplemental Content

Support Center